immunomic therapeutics crunchbase

ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. 2017 Jun 12:1-10. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. mcarey@rxir.com mkemp@immunomix.com Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. News | Astellas Pharma Inc. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. 28 Employees . J Immunol. For more information, please visit www.immunomix.com. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. Melody Carey View detailed 028300.KR description & address. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based Immunomic Therapeutics' continued investment in Process Development provides value in several ways. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. 438 followers 429 connections. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Immunomic Therapeutics is a biotech company committed to patients. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. Copied 917-322-2571, Internet Explorer presents a security risk. We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. ITI maintains its headquarters in Rockville, Maryland. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time We provide a professional and challenging work environment . ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. ITI-ID Candidate Multiple infectious diseases. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. DC Inno - Exclusive: Rockville biotech expanding, 'on the prowl' for Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Priscilla Fussell - Legal Counsel, Contracts & Intellectual Property Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. Sia Anagnostou The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. Contact Email info@immunomet.com. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). 301-968-3501 858-366-3243, Internet Explorer presents a security risk. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy today announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations. Headquarters Location. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. Immunic Therapeutics - Crunchbase Company Profile & Funding I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. 028300.KR | HLB Co. Ltd. Company Profile & Executives - WSJ ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. 717-327-1822, ITI Media: Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. This feature is in beta and may change with future updates. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Jan 2006 - Present17 years 2 months. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. ITI-2000 provides an UNITE platform address for HPV+ cancers. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Immunomic Therapeutics General Information. ITI Company: Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). To explore Immunic Therapeutics's full profile, request access. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . Phone Number +4989208047700. In addition, ITI-1001 represents a far more cost-effective approach. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. immunomic therapeutics crunchbase A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Request a free trial. Immunomic Therapeutics Inc - Company Profile and News Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. Chinatrust Executive House Hsin-Tien-New Taipei City Updated 2022 Room Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Work Here? In addition, ITI-1001 represents a far more cost-effective approach. J Immunol Res. HLB also secured an option to make further investment into the company in the months ahead. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. CONTACT - MiNA Therapeutics | RNA Activation View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. immunomic therapeutics crunchbase. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: SaaS, Android, Cloud Computing, Medical Device). Immunomic Therapeutics to present at the BIO CEO & Investor Conference In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). For more information, please visit www.immunomix.com. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. Active, Closed, Last funding round type (e.g. ITI-2000 HPV+ Tumors. Home - Immunomic Therapeutics Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. 2017 Aug;47:85-92. Great people . Immunomic Therapeutics Appoints Vice President, Cell Therapy Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. ITI maintains its headquarters in Rockville, Maryland. With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. November 30, 2021, 7:01 PM UTC. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Email credentials to careers@immunomix.com. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Mohan Karkada - Director of Research and Development - LinkedIn ImmunoMet Therapeutics - Crunchbase Company Profile & Funding Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. CONTACT US. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Description. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Innovative Cellular Therapeutics (ICT) | LinkedIn Hum Vaccin Immunother. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. What is health insurance like at Immunomic Therapeutics. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. mcarey@rxir.com Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). The company was founded in 2005 and is based in Lancaster, Pennsylvania. ITI maintains its headquarters in Rockville, Maryland. Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. You will receive a reply to confirm the receipt of your application. ITI-3000 Merkel Cell Carcinoma - pDNA. View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Join to follow . / Oct 13, 2015. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. 917-322-2571, Internet Explorer presents a security risk. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. Senior Scientist/Scientist II, Formulation Development. This day-long event includes an Advocacy Summit Liked by Priscilla Fussell News Releases | PharmaJet Pays for all health and welfare insurance premiums 100%. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Jan 30, 2015. Report this profile . -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. Immunomic Therapeutics Strengthens Leadership Team with Appointment of 15010 Broschart Road Suite 250. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Immunomic Therapeutics, Inc. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. Animal Health All. aanagnostou@immunomix.com Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Melody Carey The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Companies. Founded Date 2015. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). Founders Sungwuk Kim. This is the Immunomic Therapeutics company profile. Global Brain Cancer Market Assessment 2021-2030 - PR Newswire Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.